• Over €13 billion in investment funds available to medtech start-ups

    Medtech investors and start-ups, and some of the world’s top corporates will gather in Dublin this week at the Innovation in Medtech conference which will see over 50 medtech start-ups pitch for funding from venture capital firms with over €13 billion in funds under management.

  • Innovation in Medtech

    We are delighted to be part of 2016's Innovation In Medtech conference from 12-14 April, which will look at global market trends, and moving Irish medtech forward.

  • Beyond Borders 2016: Biotech financing

    For the second straight year, financing for the biotech sector has resulted in a record-setting “bountiful harvest”.

  • Real-world evidence: the privacy predicament

    We explore the privacy considerations of RWE to help the life sciences industry better understand the data privacy restrictions and legislations that apply.

  • Big data: helping patients and providers connect

    Life sciences companies are under increasing pressure to do more with less. See how digital strategies and accountability with analytics help bridge the communication gap.

  • Pharmaceutical R&D tax incentives

    Globalisation of the pharmaceutical industry and increased outsourcing have drastically changed the R&D landscape. This report explores the impact on R&D tax incentives.

  • The new revenue recognition standard - life sciences

    Due to the revenue recognition standards recently issued, life sciences entities may need to make changes. We highlight the key considerations and next steps.

  • Firepower and Growth Gap Report 2014

    Big pharma needs mergers and acquisitions to grow, but the deal landscape is more competitive than ever. Read more about pharma's growth gap in our report.

  • Life Sciences deal sentiment scorecard

    What lies ahead in the deal space? Our scorecard is based on investor presentations, meetings and conversations around the 2013 J.P. Morgan Healthcare Conference.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Spotlight: Innovation in Medtech

EY - Innovation In Medtech

We are delighted to be part of 2016's Innovation In Medtech conference from 12-14 April, which will look at global market trends, and moving Irish medtech forward. Read the full agenda.


Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:


  • Biotechnology

    More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.

    But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

    We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.

    We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.

    So it’s not surprising that we serve more biotech companies than any other professional services firm – by a wide margin.

    Take a closer look:

  • Pharmaceutical

    Pharmaceutical companies are facing great changes to the industry – emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

    We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business – the new business imperative of improving health outcomes.

    Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders – patients, providers, manufacturers and others – around these interventions.

    Take a closer look:

  • Medical technology

    Fundamental drivers – from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures – suggest demand for medical technology products should be robust for years to come.

    Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

    Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

    From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organisations navigate every critical stage of their business life cycle.

    Take a closer look:



Contact us

EY - Aidan Meagher

Aidan Meagher
Partner
Head of Life Sciences
International Tax Services
 +353 (1) 221 1139
linkedIn Aidan Meagher Aidan Meagher

 

EY - Graham Reid

Graham Reid
Partner
Corporate Finance
Head of Transaction Advisory Services
 +353 1 221 1449

 

EY - Feargal De Freine

Feargal De Freine
Assurance Partner
 +353 1 221 1636

 

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY - Optimise for today? Build for tomorrow?

Optimise for today? Build for tomorrow?

Whether you’re transforming your business today, or transform the sector tomorrow. EY can help you do both better.

EY - Ireland Life Sciences

Ireland Life Sciences

EY discusses the Life Sciences sector